Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 24;11:484. doi: 10.1038/s41467-019-14186-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — a Fasting blood glucose level. Two-month-old male control (RIP-Cre) and K2-RIP mice were fasted overnight. *P < 0.05, versus control, N = 8 for control, N = 7 K2-RIP, b GTT. Mice treated as in a were given intraperitoneal injections of glucose (2 g/kg body weight). *P < 0.05, versus control, N = 5 for WT and K2-RIP, N = 6 for Kindlin-2^fl/fl, and N = 7 for RIP-Cre and Kindlin-2^fl/+; RIP-Cre. c Blood insulin level. Mice were treated as in a. *P < 0.05, versus control, N = 5 mice per genotype. d ITT. Mice fasted (6–7 h) were intraperitoneally injected with a single dose of recombinant human insulin (1 U/kg body weight). *P < 0.05, versus control, N = 6 for control, N = 8 for K2-RIP. e In vivo GSIS. Mice treated as in a and intraperitoneally injected with glucose (2 g/kg body weight). Blood insulin levels were measured by ELISA at 0, 3, 5, 10, and 30 min after glucose injection. *P < 0.05, versus control, N = 5 for WT, N = 8 for RIP-Cre and K2-RIP. f In vitro GSIS. Islets isolated from 2-month-old male control K2-RIP mice were treated with 2.8 or 16.7 mM glucose. Amounts of insulin in supernatant were measured by ELISA assay. Proteins were extracted and total insulin content was measured. Supernatant insulin was normalized to total insulin content. *P < 0.05, versus 2.8 mM glucose, ^#P < 0.05, versus control. g Ca²⁺ influx. Representative results from control and K2-RIP islets are provided. N = 15 control islets, N = 20 K2-RIP islets. h Quantification of glucose (16.7 mM) stimulation in control and mutant islets. N = 6 islets for control, N = 3 islets for K2-RIP, *P < 0.05, versus control. i Quantification of KCI (20 mM) stimulation in control and mutant islets. N = 5 islets for control, N = 3 islets for K2-RIP, *P < 0.05, versus control. Results are expressed as mean ± standard deviation (s.d.) and Student’s t test was used in this figure. Source data for a–f, h, i are provided as a Source Data file.